Peptide LibraryNoopept
Noopept is a dipeptide nootropic in the Neuromodulator class. Noopept is a proline-containing dipeptide structurally related to the racetam class. It is metabolised in part to cycloprolylglycine, an endogenous dipeptide reported to modulate AMPA and NMDA receptor function.
For research use only.
Key Facts
- CAS
- 157115-85-0
- Molecular Weight (MW)
- 318.4 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 5
- Listed offers
- 10
- Price per mg (capsules)
- $0.033/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Sprays, route not stated2 vendors · $0.107–$1.85/mg
- Capsules4 vendors · $0.033/mg
Research summary
Synthetic dipeptide developed in Russia and marketed there as a nootropic. It is not FDA-approved and is not a lawful dietary supplement ingredient in the United States. Most published research is Russian-language and preclinical.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studies2 reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Noopept profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Noopept dosage: no established human dose
Noopept has no established human dosage outside Russia. No trial is registered on ClinicalTrials.gov, and the indexed human literature is three Russian-language studies. One, an open study in 60 stroke patients with mild cognitive impairment, reports 20 mg a day for 2 months; the others do not give a dose in the indexed record. It is not approved in the United States or the European Union.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic dipeptide-derived compound developed in Russia, with most of its literature from rodent memory and neuroprotection models. The human studies are small, open or uncontrolled, published in Russian, and not replicated in trials registered internationally. A single open study reports a dose, which is not enough to establish one.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Oral (the route in the Russian clinical literature) |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-11-07 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Open prospective study — mild cognitive impairment after stroke (2011)Clinical trial · Open-label prospective study with a control group, Russian-language publication | Patients with mild cognitive impairment after stroke (n=60) | 20 mg a day | Not stated in the indexed record | Daily | 2 months (study follow-up 12 months) | Cognitive test scores (MMSE and verbal association tasks) | Noopept in the treatment of mild cognitive impairment in patients with stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2011. |
| EEG study — mild cognitive impairment of traumatic or vascular origin (2008)Clinical trial · Clinical study, Russian-language publication | Patients with mild cognitive impairment after brain trauma or vascular disease | Not stated in the indexed record | Not stated in the indexed record | — | — | EEG rhythm changes | Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. |
Where sources disagree
- Doses of 10–30 mg a day are commonly published for noopept. The only indexed human study that states a dose used 20 mg a day in stroke patients, in an open-label design without a placebo.
- No regulator in the United States or the European Union has approved noopept, and no trial of it is registered on ClinicalTrials.gov.
Sequence & molecular data
| Molecular formula | C17H22N2O4 |
|---|---|
| Molecular weight | 318.4 g/mol |
| CAS number | 157115-85-0 |
| PubChem CID | 180496 |
| FDA UNII | 4QBJ98683M |
| ChEMBL | CHEMBL4303687 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Noopept is a proline-containing dipeptide structurally related to the racetam class. It is metabolised in part to cycloprolylglycine, an endogenous dipeptide reported to modulate AMPA and NMDA receptor function. Preclinical studies describe increased expression of brain-derived neurotrophic factor and nerve growth factor in the hippocampus, and antioxidant effects; controlled human efficacy data outside Russia is essentially absent.
Studies
- Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) - An active pharmaceutical ingredient with nootropic activity
- Effects of noopept on ocular, pancreatic and renal histopathology in streptozotocin induced prepubertal diabetic rats
- Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat
- Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats
- Cognitive Enhancer Noopept Activates Transcription Factor HIF-1
Research statistics
86 PubMed publications · 10.6% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Noopept is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Research status | Research-only compound; no approval pathway listed |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
—
Noopept side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Noopept: frequently asked questions
What is Noopept?
Synthetic dipeptide developed in Russia and marketed there as a nootropic. It is not FDA-approved and is not a lawful dietary supplement ingredient in the United States. Most published research is Russian-language and preclinical.
How does Noopept work?
Noopept is a proline-containing dipeptide structurally related to the racetam class. It is metabolised in part to cycloprolylglycine, an endogenous dipeptide reported to modulate AMPA and NMDA receptor function.
Is Noopept FDA approved?
No. Noopept is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Noopept?
Compounds most often compared with Noopept include Selank, N-Acetyl Selank Amidate, Semax and Tuftsin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) - An active pharmaceutical ingredient with nootropic activity — J Pharm Biomed Anal, 2025External reference
- Effects of noopept on ocular, pancreatic and renal histopathology in streptozotocin induced prepubertal diabetic rats — Biotech Histochem, 2023External reference
- Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat — Neurosci Lett, 2022External reference
- Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats — Int J Mol Sci, 2022External reference
- Cognitive Enhancer Noopept Activates Transcription Factor HIF-1 — Dokl Biochem Biophys, 2020External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Noopept profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Noopept research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →